Next Post

VectivBio Reports Full Year 2021 Financial Results and Provides Business Update

VectivBio AG Significant Progress Across Multiple Programs with Key Upcoming Catalysts Beginning H2 2022 STARS Phase 3 Program of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) On-Track for Topline Results at End of 2023 Cash Runway Extends Beyond Anticipated Release of Topline STARS Phase 3 Data Management to […]

You May Like

Subscribe US Now